“We recently hosted a series of mtgs w/ investors and Theravance mgmt. TD-1473 JAK inhibitor and GSK respiratory programs were typical starting points for discussion. Mgmt plans to initiate TD-1473 Phase 2b induction/ maintenance trial in Ulcerative Colitis in mid-2018. Initial data from TD-1473 Phase 1b trial in this indication are consistent w/activity in our opinion. Number of doses and patients in Phase 2b trial will depend on data from additional Phase 1b cohorts, which mgmt has not yet seen. GSK launched Trelegy for COPD last month (5.5-8.5% royalty to Theravance). Significant time also spent on TD-9855 and velusetrag, both of which appear on path for Phase 3 initiation in 2018. Reiterate BUY. We believe stock is undervalued ($1.3B EV), given continued maturation of diversified pipeline.”,” the firm’s analyst wrote.
Several other brokerages also recently commented on TBPH. ValuEngine raised shares of Theravance Biopharma from a sell rating to a hold rating in a report on Wednesday, September 13th. Zacks Investment Research raised shares of Theravance Biopharma from a sell rating to a hold rating in a report on Tuesday, September 19th. Robert W. Baird reissued a sell rating and issued a $22.00 price objective on shares of Theravance Biopharma in a report on Wednesday, November 1st. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the company a buy rating in a report on Wednesday, October 25th. Finally, Evercore ISI initiated coverage on shares of Theravance Biopharma in a report on Wednesday, August 16th. They issued an outperform rating and a $45.00 price objective for the company. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $41.86.
Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in shares of Theravance Biopharma by 3.6% during the 2nd quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock worth $144,972,000 after acquiring an additional 126,393 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Theravance Biopharma by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock worth $127,379,000 after acquiring an additional 116,981 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Theravance Biopharma by 174.8% during the 2nd quarter. Wells Fargo & Company MN now owns 88,688 shares of the biopharmaceutical company’s stock worth $3,533,000 after acquiring an additional 56,418 shares during the period. Alps Advisors Inc. bought a new stake in shares of Theravance Biopharma during the 2nd quarter worth approximately $1,915,000. Finally, State of Wisconsin Investment Board bought a new stake in shares of Theravance Biopharma during the 2nd quarter worth approximately $1,235,000. 86.37% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/06/theravance-biopharma-tbph-receives-buy-rating-from-needham-company-llc.html.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.